OR YEHUDA, Israel, November 9, 2015 /PRNewswire/ --
A unique source of collagen fibers was discovered to be abundant in soft corals. Collagen is known for its use in many medical applications for many years. This new collagen holds promising opportunities in new medical uses.
The fibers were discovered by Professor Yehuda Bnayahu, together with Ido Sella, Ph.D. of Tel Aviv University. Their research discovered unique fibers in a soft coral. They confirmed the fibers were collagen and understood the great potential of the fibers for medical use. Gilad Karni, an experienced medical device executive, recognized the potential of the fibers and founded ExceeMatrix in order to optimize medical solution based on collagen or other biomaterials.
Collagen is the most common protein in animals and humans, making up to 25-35% of the whole body protein content. Collagen is a structural protein, which is the main building block of connective tissues, including bone, skin, blood vessels, tendon, ligaments, etc.
As opposed to mammalian collagen sources, the coral collagen does not go through break down, reconstitution and crosslinking. The development process of the coral collagen is cost effective and faster towards market approval. ExceeMatrix uses an innovative cleaning process that allows the coral collagen to maintain its unique mechanical properties.
The first product in the pipeline is an Anterior Cruciate Ligament (ACL) implant for ACL (knee) reconstruction.
There were over 400,000 ACL reconstructions in the US last year, and 300,000 in Europe. This sport injury is becoming more and more prevalent due to the increase in number of older athletes. Today, the graft used for reconstruction is harvested from a cadaver or from the own patient causing a secondary site of surgery, pain and recovery. The ExceeMatrix ACL implant has the potential to overshadow the existing solutions, and offer a great off the shelf solution without tissue harvesting and elimination of disease transmission.
The potential expenditures for ACL autografts and allografts are estimated to total over $3 billion worldwide. The market is looking for alternatives that do not require the surgical procedure of autografts or the use of cadaver source in allografts. ExceeMatrix holds an optimal solution by providing both the high tensile strength needed for ACL reconstruction, and regeneration induced by the collagen.
Karni: "ExceeMatrix has made great progress. The ACL implant is only the first in the company's pipeline and is intended for clinical trial by 2017."
ExceeMatrix is an innovative medical device company. ExceeMatrix is focused on providing a solution for ligaments and tendon repair.